Navigation Links
PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
Date:1/19/2010

s ground-breaking study in DBMD patients who have lost the ability to walk," said Valerie Cwik, M.D., Executive Vice President -- Research and Medical Director, Muscular Dystrophy Association.  "This trial underscores the importance of MDA's translational research effort.  In April 2005, MDA awarded an initial $1.5 million grant to PTC in support of early clinical development of ataluren in nmDBMD.  Now we have a trial that will provide valuable information on older DBMD boys and young men that will assist in the design of future clinical trials."

This one-year, Phase 2a study is evaluating the safety, pharmacodynamic activity, and pharmacokinetics of ataluren, an investigational new drug, while assessing the use of several outcome measures of physical, pulmonary, and cardiac function in patients with advanced disease.  Approximately 30 patients are being enrolled in the trial at five sites in the United States, which are part of the MDA's DMD Research Network, and at one site in the United Kingdom.  Additional information on this study can be found on http://clinicaltrials.gov.

"We are eager to participate in this innovative study of non-ambulatory DMD patients," stated John W. Day, M.D., Ph.D., principal investigator at the University of Minnesota's Paul and Sheila Wellstone Muscular Dystrophy Center.  "This precedent-setting trial is an important extension of current studies of younger, ambulatory boys with DMD, and will help define methods
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
2. Echo Therapeutics Announces Major Milestone: The Completion of Product Development Work of its Revolutionary, Patented Prelude(TM) SkinPrep System
3. Advanced Cardiac Therapeutics Completes $5 Million Financing
4. Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference
5. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
6. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
7. Cell Therapeutics, Inc. Adopts Shareholder Rights Plan
8. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
9. PTC Therapeutics Closes $50 Million Financing
10. Fate Therapeutics iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs
11. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (NYSE: RMD ) today announced results for its ... was $453.1 million, a 9 percent increase compared with ... increase on a constant currency basis).  Net income was ... 2014.  Diluted earnings per share for the quarter were ... The results for the quarter ended ...
(Date:7/30/2015)... we bring you a special edition of #MedicareMonday on Medicare,s 50 th anniversary. ... Medicare resources and continue highlighting the success of the prescription drug benefit, commonly referred ... out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19
... Texas, Feb. 23, 2012   ULURU Inc. (NYSE ... Goods Certificate has been issued by the Therapeutic Goods ... Commenting on the approval in Australia, Kerry P. ... another important milestone in the worldwide commercialization of Altrazeal®.  ...
... Feb. 23, 2012 A new imaging efficiency ... Medicaid Services (CMS) to reduce CT scans in ... are performing CT scans inappropriately, according to a ... of Emergency Medicine ("Assessment of Medicare,s Imaging ...
Cached Medicine Technology:ULURU Inc. Announces Approval to Market Altrazeal® in Australia 2ULURU Inc. Announces Approval to Market Altrazeal® in Australia 3Government Rule Designed to Limit CT Scans in ERs Is Unreliable, Invalid and Inaccurate, Says ACEP 2
(Date:7/31/2015)... , ... July 31, 2015 , ... In the most ... U.S. District Court in the Northern District of Illinois, Androgel testosterone attorneys report that ... 20, a docket entry was made recording the minutes of the status conference, which ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions announced today ... of Microsoft Dynamics GP for a senior living facility in Maine. Having achieved ... living communities in 16 states. This further expansion was again a factor of ...
(Date:7/30/2015)... ... ... When responsible for the care of an aging loved one, summer vacations ... What happens if mom falls? Who will remind Dad to take his medications? What ... not taking time away from caregiving responsibilities can lead to bigger problems – caregiver ...
(Date:7/30/2015)... ... 2015 , ... On July 22nd the Bradenton Herald reported the ... for controlling the heroin outbreak. Ultimately the committee expressed lack of funding, and the ... heroin crisis in North Florida. The task force has proposed to instate counselors to ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... BioPharma, Inc. are pleased to announce that data standards for clinical research in ... on the CDISC website . These three Therapeutic Area (TA) standards were ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5
... for Public-Private Partnerships at The Henry M. Jackson Foundation ... to announce the recipients of the 2012 Heroes of ... excellence and selfless dedication to advancing medicine for our ... their families. The recipients will be honored at the ...
... 6, 2012 Discoveries made in the laboratories of ... the first time, advance to the clinical research stage ... Translational Research Institute for Metabolism and Diabetes (TRI). The ... in the brain, which appears to resolve obesity without ...
... MONDAY, March 5 (HealthDay News) -- New guidelines for colorectal ... the emphasis on individual risk. People at average risk ... 50, whereas people at high risk -- those with inflammatory ... disease -- should get screened starting at age 40 or ...
... Doctors are more likely to order imaging and other diagnostic ... to the test results, according to a new study. ... efficiency, researchers from Harvard Medical School found easy access to ... percent increase in imaging test orders. Computerization actually could be ...
... today issued a new guidance statement for colorectal cancer ... cancer-related deaths for men and women in the United ... in the March 6 issue of Annals of ... this guidance statement to present information to physicians and ...
... March 5 (HealthDay News) -- Patients suffering from advanced ... physicians, so everyone is on the same page with ... The advice is outlined in a "scientific statement" ... "For patients with advanced heart failure, the decision-making ...
Cached Medicine News:Health News:HJF Center announces Heroes of Military Medicine award recipients 2Health News:Sanford-Burnham research advances to patient studies at TRI 2Health News:Sanford-Burnham research advances to patient studies at TRI 3Health News:New Colon Cancer Screening Guidelines Focus on Individual Risk 2Health News:New Colon Cancer Screening Guidelines Focus on Individual Risk 3Health News:Computerization May Not Curb Medical Tests, Costs 2Health News:American College of Physicians releases new colorectal cancer screening guidance statement 2Health News:Heart Failure Patients Urged to Discuss Care With Docs 2
... Microalbumin Strips provide albumin, creatinine and albumin-to-creatinine ... Microalbumin product is useful to test for ... in order to detect early kidney disease. ... the urinary albumin excretion rate, is an ...
... to near-patient urinalysis. The Chemstrip ... affordable, reliable alternative to visual ... fundamental, easy-to-use features, the Chemstrip ... office lab, clinic, and hospital ...
... UA is the first hand-held urine ... valuable lab bench space. Automation of ... in results between operators and transcription ... run, corrects for ambient temperature and ...
... first outside-the-balloon, dual-wire dilatation catheter. The ... innovative new approach to dilatation. Its unique, ... wires to create expansion planes at low ... ,The FX miniRAIL RX PTCA Catheter is ...
Medicine Products: